• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.

作者信息

Zhang Mu-Chen, Fang Ying, Xu Peng-Peng, Dong Lei, Shen Rong, Huang Yao-Hui, Fu Di, Yan Zi-Xun, Cheng Shu, Jiang Xu-Feng, Song Qi, He Yang, Zhao Yan, Lu Min, Ye Jing, Liu Feng, Cheng Lin, Wang Chao-Fu, Wang Li, Zhao Wei-Li

机构信息

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

出版信息

Clin Transl Med. 2021 Dec;11(12):e584. doi: 10.1002/ctm2.584.

DOI:10.1002/ctm2.584
PMID:34923760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8684715/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/5a7d2b7deeb0/CTM2-11-e584-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/8cd32b813216/CTM2-11-e584-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/b91b73b0e7a0/CTM2-11-e584-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/5a7d2b7deeb0/CTM2-11-e584-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/8cd32b813216/CTM2-11-e584-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/b91b73b0e7a0/CTM2-11-e584-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cec2/8684715/5a7d2b7deeb0/CTM2-11-e584-g002.jpg

相似文献

1
Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.地西他滨联合R-CHOP方案治疗初诊弥漫性大B细胞淋巴瘤患者的临床疗效及肿瘤微环境影响：1/2期及生物标志物研究
Clin Transl Med. 2021 Dec;11(12):e584. doi: 10.1002/ctm2.584.
2
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.在接受 CHOP 或 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者中，BCL6 重排与预后的相关性。
Haematologica. 2010 Jan;95(1):96-101. doi: 10.3324/haematol.2009.007203. Epub 2009 Oct 1.
3
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
4
Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.细胞因子基因多态性作为接受（R）-CHOP治疗的弥漫性大B细胞淋巴瘤患者的预后标志物
Ann Hematol. 2017 Feb;96(2):227-235. doi: 10.1007/s00277-016-2857-x. Epub 2016 Nov 7.
5
How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.基因多态性如何影响弥漫性大B细胞淋巴瘤患者接受R-CHOP治疗后的临床反应和毒性。
Blood Rev. 2017 Jul;31(4):235-249. doi: 10.1016/j.blre.2017.02.005. Epub 2017 Feb 27.
6
Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.肿瘤微环境中免疫细胞特征对弥漫性大 B 细胞淋巴瘤的影响。
Hematol Oncol. 2021 Dec;39(5):616-624. doi: 10.1002/hon.2905. Epub 2021 Jul 31.
7
A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.一项评估塔西美妥单抗（EPZ-6438）联合 R-CHOP 方案治疗伴有预后不良特征的新诊断弥漫性大 B 细胞淋巴瘤（DLBCL）患者的 LYSA Ib 期研究。
Clin Cancer Res. 2020 Jul 1;26(13):3145-3153. doi: 10.1158/1078-0432.CCR-19-3741. Epub 2020 Mar 2.
8
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.CHOP-R疗法克服了弥漫性大B细胞淋巴瘤中BCL-2表达的不良预后影响。
Leuk Lymphoma. 2007 Jun;48(6):1102-9. doi: 10.1080/10428190701344881.
9
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.修订后的国际预后指数和基因突变与弥漫性大 B 细胞淋巴瘤患者 R-CHOP 早期失败相关。
Br J Haematol. 2022 Feb;196(3):589-598. doi: 10.1111/bjh.17858. Epub 2021 Oct 10.
10
[Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].利妥昔单抗联合CHOP方案与单纯CHOP方案治疗初治弥漫性大B细胞淋巴瘤患者的比较
Ai Zheng. 2005 Dec;24(12):1498-502.

引用本文的文献

1
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06).基因亚型指导的免疫化疗用于复发难治性弥漫性大B细胞淋巴瘤：一项2期研究者发起的非随机临床试验（GUIDANCE-06）
Signal Transduct Target Ther. 2025 Jul 26;10(1):232. doi: 10.1038/s41392-025-02316-6.
2
Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study.在不符合移植条件的复发/难治性弥漫性大B细胞淋巴瘤中，阿扎胞苷序贯R-GDP方案：一项多中心II期研究的初步结果
Ther Adv Hematol. 2025 Jul 11;16:20406207251349361. doi: 10.1177/20406207251349361. eCollection 2025.
3

本文引用的文献

1
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.关于改进R-CHOP方案的观点：从大剂量CHOP到强力R-CHOP，“凤凰”尚未升起。
Lancet Haematol. 2020 Nov;7(11):e838-e850. doi: 10.1016/S2352-3026(20)30222-2.
2
Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1.SOCS1 部分功能缺失个体中的免疫失调和儿童多系统炎症综合征 (MIS-C)。
J Allergy Clin Immunol. 2020 Nov;146(5):1194-1200.e1. doi: 10.1016/j.jaci.2020.07.033. Epub 2020 Aug 25.
3
Genetic alterations and their clinical implications in DLBCL.
CD5 and p53 immunohistochemistry: valuable prediction method in molecular typing of CD5-positive diffuse large B-cell lymphoma.CD5和p53免疫组织化学：CD5阳性弥漫性大B细胞淋巴瘤分子分型中有价值的预测方法。
BMC Cancer. 2025 Apr 17;25(1):726. doi: 10.1186/s12885-025-13990-8.
4
Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing.提高新诊断的大B细胞淋巴瘤患者的治愈率：针对临床实验室检测所定义的高危病理亚组的靶向治疗。
Cancers (Basel). 2024 Dec 24;17(1):18. doi: 10.3390/cancers17010018.
5
Integration of multi-omics transcriptome-wide analysis for the identification of novel therapeutic drug targets in diabetic retinopathy.整合多组学全转录组分析以鉴定糖尿病视网膜病变中的新型治疗药物靶点。
J Transl Med. 2024 Dec 24;22(1):1146. doi: 10.1186/s12967-024-05856-7.
6
Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.初诊大 B 细胞淋巴瘤伴或不伴后续疾病进展的基因组特征。
Cancer Res Commun. 2024 Nov 1;4(11):2947-2954. doi: 10.1158/2767-9764.CRC-24-0337.
7
Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial.靶向药物联合CHOP方案与CHOP方案作为初治外周T细胞淋巴瘤患者一线治疗的比较（GUIDANCE-03）：一项开放标签、多中心2期临床试验
Lancet Reg Health West Pac. 2024 Jul 29;50:101160. doi: 10.1016/j.lanwpc.2024.101160. eCollection 2024 Sep.
8
Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome.分子亚型及TP53在弥漫性大B细胞淋巴瘤和里氏综合征中的作用
Cancers (Basel). 2024 Jun 7;16(12):2170. doi: 10.3390/cancers16122170.
9
Endogenous Retroviruses Unveiled: A Comprehensive Review of Inflammatory Signaling/Senescence-Related Pathways and Therapeutic Strategies.内源性逆转录病毒揭秘：炎症信号/衰老相关通路及治疗策略的全面综述
Aging Dis. 2024 May 14;16(2):738-756. doi: 10.14336/AD.2024.0123-1.
10
Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中肿瘤微环境组成和功能的遗传机制。
Blood. 2024 Mar 21;143(12):1101-1111. doi: 10.1182/blood.2023021002.
弥漫性大 B 细胞淋巴瘤中的遗传改变及其临床意义。
Nat Rev Clin Oncol. 2019 Oct;16(10):634-652. doi: 10.1038/s41571-019-0225-1.
4
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.弥漫性大B细胞淋巴瘤患者蒽环类药物剂量优化：一项多中心、3期、随机对照试验。
Lancet Haematol. 2019 Jun;6(6):e328-e337. doi: 10.1016/S2352-3026(19)30051-1.
5
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy.IFNγ：信号转导、表观遗传学及其在免疫、代谢、疾病和癌症免疫治疗中的作用。
Nat Rev Immunol. 2018 Sep;18(9):545-558. doi: 10.1038/s41577-018-0029-z.
6
Increased IFNγ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy.低剂量去甲基化药物地西他滨抗肿瘤治疗的临床疗效与 IFNγ T 细胞的增加有关。
Clin Cancer Res. 2017 Oct 15;23(20):6031-6043. doi: 10.1158/1078-0432.CCR-17-1201. Epub 2017 Jul 13.
7
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
8
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.新兴疗法为重塑免疫系统和淋巴瘤细胞之间多方面的相互作用提供了新的机会。
Leukemia. 2016 Sep;30(9):1805-15. doi: 10.1038/leu.2016.161. Epub 2016 Jun 8.
9
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.抑制DNA甲基化会通过包括内源性逆转录病毒在内的双链RNA在癌症中引发干扰素反应。
Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011.
10
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.基于机制的弥漫性大 B 细胞淋巴瘤表观遗传化学增敏治疗。
Cancer Discov. 2013 Sep;3(9):1002-19. doi: 10.1158/2159-8290.CD-13-0117. Epub 2013 Aug 16.